Vicore Pharma is a clinical-stage biopharmaceutical company developing treatments for respiratory and fibrotic diseases. Its lead candidate, buloxibutid, is an oral angiotensin II type 2 (AT2) receptor agonist studied for idiopathic pulmonary fibrosis (IPF), with FDA Orphan Drug and Fast Track designations. The company focuses on a new drug class intended to modify disease course rather than only ease symptoms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 5.1 | — | -84.1 | — |
| Q1 2025 | 0.9 | — | -111.5 | — |
| Q2 2025 | 1.8 | — | -115.4 | — |
| Q4 2025 | 0.4 | -91.8% | -137.1 | — |
| Q1 2026 | 0.6 | -32.5% | -108.6 | — |
All markets — KeepWinning global stock screener
Other companies on Stockholm: XANO Industri AB (publ) (XANO B), Keo Capital AB (publ) (KEOC), Brinova Fastigheter AB (publ) (BRIN B), ALM Equity AB (publ) (ALM PREF), Neobo Fastigheter AB (publ) (NEOBO), K-Fast Holding AB (publ) (KFAST B)